Biotechnology
Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes Excerpt from the Press Release: SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, today announced…
Read More
Excerpt from the Press Release: South San Francisco, CA — April 24, 2025 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).The trial met its primary endpoint,…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel,…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona’s proprietary H2L2…
Read More
Excerpt from the Press Release: SAN FRANCISCO, April 1, 2025 /PRNewswire/ — Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug Administration (FDA) to initiate a global registration…
Read More TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete…
Read More
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently available…
Read More New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks Excerpt from the Press Release: BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, unveiled a potential game-changer in…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, will highlight progress across its clinical pipeline, including continued advancement of…
Read More